|Bid||0.00 x 1000|
|Ask||0.00 x 900|
|Day's Range||8.79 - 9.19|
|52 Week Range||8.02 - 14.97|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 15, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Subscribe to Yahoo Finance Plus to view Fair Value for WELearn more
Potential WeWork Inc. ( NYSE:WE ) shareholders may wish to note that the CEO & Director, Sandeep Mathrani, recently...
(Bloomberg) -- SoftBank Group Corp.’s Masayoshi Son has bet on everything from chip companies to office-space provider WeWork Inc., but has taken an unusual turn with his latest foray: sleep disorders.Most Read from BloombergChina Cash Flowed Through Congo Bank to Former President’s CroniesBillionaire Family Feud Puts a Century-Old Business Empire in JeopardyJapan’s Aculys Pharma LLC, backed by SoftBank’s second Vision Fund, bought the rights to develop and sell pitolisant, used to treat narcole
CEO Sandeep Mathrani bought 29,600 shares at $8.46 each, boosting his position to 1.76 million shares.